NAD+ · Research brief

How to Read NAD+ COA — Purity, Potency & Lab Standards

Real Peptides Research TeamEditorial

Updated July 6, 202610 min read

55 WORDS

Short answer

Key takeaways

HPLC is the minimum acceptable analytical method for NAD+ purity verification. Spectrophotometry and UV absorbance cannot differentiate the target compound from structurally similar impurities.
Research-grade NAD+ should demonstrate ≥98% purity by HPLC, with individual impurities quantified and not exceeding 0.5% each per USP Chapter 1225 standards.
Heavy metal contamination (lead, arsenic, cadmium, mercury) must be quantified in numeric ppm values. COAs listing 'conforms' or 'passes' without measurements are not verifiable.
Endotoxin levels below 50 EU/mg are critical for cell culture and immunological research applications, as bacterial endotoxin interferes with assays at concentrations well below visible contamination thresholds.
Batch number on the COA must match the label on your vial, and the test date should be within 12 months of receipt to ensure the analysis reflects current peptide quality, not outdated stock.
A COA missing any of these elements. Assay method, numeric purity, quantified contaminants, or batch traceability. Is not a quality assurance document; it's marketing material on letterhead.

Most researchers don't realise their NAD+ failed before they ever injected it. The issue wasn't the protocol or the storage. It was the compound itself, and the certificate of analysis warned them if they'd known how to read it. A COA showing '98% purity' without specifying the analytical method used isn't a quality assurance document. It's a marketing claim on letterhead, and accepting it means accepting unknown contaminants, degraded peptides, or worse. The wrong molecule entirely.

We've guided hundreds of research teams through peptide sourcing and quality verification. The difference between a compound that performs reliably and one that fails mid-study comes down to three COA elements most suppliers hope you don't scrutinise: the assay method, the specification limits, and the quantified impurity profile.

How do you read NAD+ COA reports to verify research-grade quality?

To read NAD+ COA reports correctly, first verify the analytical method is HPLC (high-performance liquid chromatography). Not spectrophotometry or visual inspection. Then confirm purity percentage meets or exceeds 98%, check that heavy metal contaminants (lead, arsenic, cadmium) are quantified below USP limits, and ensure the batch number on the vial matches the batch tested. A valid COA also includes the testing date, storage conditions, and an expiration timeframe based on stability data.

Here's what distinguishes a legitimate NAD+ COA from a fabricated one: legitimate reports specify the exact column chemistry and mobile phase used in HPLC analysis, list retention time for the target compound, and quantify individual impurities rather than grouping them as 'other substances'. The absence of these details doesn't mean the peptide is low quality. It means you have no evidence of quality whatsoever. This article covers the exact parameters to check, the acceptable ranges for each, and the red flags that disqualify a COA before you place an order.

Step 1: Verify the Analytical Method Used (HPLC or MS Required)

The first line you look for on any NAD+ certificate of analysis is the assay method. If the COA states 'spectrophotometry', 'UV absorbance', or 'visual inspection' as the testing method, the purity claim is unreliable. These methods measure bulk properties. They can't differentiate NAD+ from structurally similar degradation products or contaminants with overlapping absorption spectra.

HPLC (high-performance liquid chromatography) is the minimum standard for peptide purity verification because it physically separates compounds based on molecular structure before quantifying them. A proper HPLC-based COA specifies the column type used. Reverse-phase C18 is standard for NAD+ analysis. And lists the mobile phase composition, typically a gradient of water and acetonitrile with trifluoroacetic acid as a modifier. If these details are absent, the report isn't traceable to a validated method.

Mass spectrometry (MS) provides molecular weight confirmation and is the gold standard for identity verification, but it doesn't replace HPLC for purity quantification. The strongest COAs combine both: HPLC to measure purity percentage and quantify impurities, MS to confirm the correct molecular formula. Our team routinely sees suppliers claim '99% purity by MS' without HPLC data. That's molecular weight confirmation, not purity measurement, and the distinction matters when you're working with compounds where a single amino acid substitution changes activity entirely.

Step 2: Decode Purity Percentage and Specification Limits

A purity percentage on a NAD+ COA represents the mass fraction of the target compound relative to total sample weight. Research-grade NAD+ should meet or exceed 98% purity by HPLC, meaning 98 grams of every 100 grams is the intended nicotinamide adenine dinucleotide molecule. Anything below 95% introduces too much variability for reproducible research. The remaining 2–5% isn't inert filler, it's unidentified substances that may interact with your assay or degrade faster than the target compound.

But here's what most researchers miss: purity percentage alone doesn't tell you what the impurities are. A COA showing 98.2% purity could have 1.8% water content and trace salts. Acceptable. Or it could have 1.8% oxidised NAD+, nicotinamide riboside, or bacterial endotoxin. Not acceptable. The critical section is the impurity profile breakdown, which should quantify at least three categories: related substances (structural analogues or degradation products), residual solvents (acetonitrile, methanol, DMF), and heavy metals (lead, arsenic, cadmium, mercury). If the COA lists 'total impurities <2%' without itemising them, you're working blind.

USP (United States Pharmacopeia) Chapter 1225 sets the reference standard for peptide purity: individual unspecified impurities must not exceed 0.5%, and total impurities must not exceed 2.0%. Real Peptides adheres to these thresholds across our entire peptide collection because reproducibility depends on batch-to-batch consistency. Not just meeting a spec once, but hitting it reliably every synthesis cycle.

Step 3: Interpret Heavy Metal and Microbial Contamination Data

NAD+ synthesis involves metal catalysts and organic solvents, both of which leave residues if purification isn't exhaustive. A complete COA quantifies four heavy metals explicitly: lead (Pb), arsenic (As), cadmium (Cd), and mercury (Hg). USP General Chapter <232> sets daily exposure limits for these elements, and while peptides used in research aren't ingested, the limits provide a safety benchmark: lead should not exceed 10 ppm, arsenic 15 ppm, cadmium 5 ppm, mercury 30 ppm.

If the COA states 'heavy metals: conforms' or 'passes' without numeric values, it's not compliant with ICH Q3D guidelines. The word 'conforms' means the lab tested for something and decided it met an internal standard. But without seeing the actual measurement, you can't verify that claim or compare batches. We've encountered NAD+ samples with lead concentrations above 25 ppm that still had COAs marked 'conforms' because the supplier's internal limit was set at 50 ppm. That's technically accurate and completely useless.

Microbial contamination is the other silent failure mode. NAD+ is synthesised via enzymatic or fermentation processes that introduce bacterial endotoxin risk. A valid COA includes total aerobic microbial count (TAMC), total yeast and mold count (TYMC), and endotoxin level measured in EU/mg (endotoxin units per milligram). For non-sterile research peptides, TAMC should not exceed 1000 CFU/g, TYMC should not exceed 100 CFU/g, and endotoxin should be below 50 EU/mg. If these aren't listed, the peptide wasn't tested for them. And bacterial endotoxin can interfere with cell culture assays at concentrations well below what causes visible contamination.

How to Read NAD+ COA: Full Comparison Table

Parameter	Minimum Acceptable Standard	Red Flag Indicator	Testing Method Required	Why It Matters
Purity (%)	≥98.0% by HPLC	<95% or method not specified	HPLC with UV detection at 260 nm	Below 98%, impurity concentration affects reproducibility and may introduce assay interference
Assay Method	HPLC (reverse-phase C18 column)	Spectrophotometry, UV absorbance only, or no method listed	HPLC with gradient elution and specified retention time	Non-chromatographic methods can't differentiate NAD+ from degradation products or structural analogues
Heavy Metals (Pb, As, Cd, Hg)	Quantified values ≤ USP <232> limits (Pb <10 ppm, As <15 ppm, Cd <5 ppm, Hg <30 ppm)	'Conforms' or 'Passes' without numeric values	ICP-MS (inductively coupled plasma mass spectrometry)	Metal contamination from catalysts used in synthesis; chronic exposure risk and assay interference
Residual Solvents	Acetonitrile <410 ppm, Methanol <3000 ppm, DMF <880 ppm per ICH Q3C	Not listed or 'within limits' without values	Gas chromatography (GC) with flame ionisation detection	Solvents used in purification; high residuals indicate incomplete drying and degrade peptide stability over time
Endotoxin Level	<50 EU/mg for research use	Not tested or '>100 EU/mg'	Limulus Amebocyte Lysate (LAL) assay	Bacterial endotoxin from fermentation process; interferes with cell culture and immune assays even at low levels
Batch Traceability	Batch number, test date, expiration date all present	Generic COA with no batch number or test date older than 12 months	N/A. Documentation requirement	Without batch traceability, you can't verify the COA corresponds to the vial you received

What If: NAD+ COA Scenarios

What If the COA Shows 96% Purity — Is That Close Enough?

No. Use it only if your research question doesn't require precise dosing or if you're doing preliminary screening work. The 2–4% gap between 96% and research-grade 98% purity isn't just 'slightly lower quality'. It's double the impurity load, and you don't know what those impurities are. If the study involves dose-response curves, receptor binding assays, or metabolic pathway tracing, that unknown 4% introduces uncontrolled variables that can shift your results outside the confidence interval. We've seen researchers attribute unexpected cytotoxicity to NAD+ itself when the actual cause was a nicotinamide degradation product present at 3% concentration in a low-purity batch.

What If the Supplier Sends a COA But the Batch Number Doesn't Match My Vial?

Request the correct COA immediately and do not use the peptide until you have batch-matched documentation. A mismatched COA means one of three things happened: the supplier sent you the wrong batch documentation by mistake, they're recycling old COAs across multiple batches without retesting, or the vial you received isn't what the label claims. None of these scenarios ends with reliable research data. Batch numbers exist specifically to link the tested sample to the shipped product. Without that traceability, you're injecting an unknown compound with unknown purity into your system.

What If the COA Doesn't List Endotoxin Levels?

Assume the peptide contains bacterial endotoxin above research-safe thresholds and either request endotoxin testing or use it only in non-biological assays. NAD+ synthesised via enzymatic or fermentation routes inherently carries endotoxin risk, and absence of testing doesn't mean absence of contamination. It means the supplier didn't check. Endotoxin at concentrations as low as 10–20 EU/mg can trigger inflammatory cytokine release in cell culture models, confounding immunology studies, and even higher levels are common in peptides purified without specific endotoxin removal steps like polymyxin B affinity chromatography.

The Unfiltered Truth About NAD+ Certificates of Analysis

Here's the honest answer: most COAs in the research peptide market aren't quality assurance documents. They're confidence props. A significant percentage of suppliers generate COAs by testing a single 'golden batch' once, then reissuing that same report with updated dates for every subsequent batch without retesting. The giveaway is identical purity percentages across multiple batches. Real peptide synthesis introduces batch-to-batch variability of ±0.5–1.0%, so seeing 98.7% purity reported for six consecutive batches over eight months isn't precision manufacturing. It's copy-paste documentation.

The NAD+ market specifically has been flooded with low-barrier suppliers since 2022 when NAD+ supplementation gained mainstream attention. Many of these operations source bulk powder from contract manufacturers, repackage it, and print generic COAs with their logo at the top. If you ask for the raw HPLC chromatogram or the MS spectrum and the supplier can't produce it within 48 hours, they likely don't have it. Because they didn't run the test. Real verification requires the actual analytical data behind the summary report: the chromatogram showing peak separation, the integration report quantifying each peak, and the mass spectrum confirming molecular weight. Without those, the COA is a trust-me document, and trust isn't a variable you control in experimental design.

This isn't a theoretical concern. In our experience working with research institutions across multiple therapeutic areas, peptide quality failure is the single most common undiagnosed cause of non-reproducible results. The study design was sound, the controls were appropriate, the statistics were valid. But the compound didn't match the COA, and every conclusion drawn from that data is now suspect. We don't say this to sell you our specific peptides. We say it because if you're going to invest months into a research question, the foundational assumption that your NAD+ is actually NAD+ at the stated purity needs to be verified, not assumed.

Closing Paragraph

The best COA in peptide research isn't the one with the highest purity number. It's the one you can independently verify matches the compound in your vial. That means batch traceability, HPLC chromatograms you can request and review, and quantified contaminant data that doesn't hide behind 'conforms' language. If the supplier treats a COA request like you're asking for proprietary trade secrets instead of standard quality documentation, you've learned what you need to know about their manufacturing standards. Explore high-purity research peptides where batch-specific COAs are provided with every order, not upon request. Because reproducible research starts with verifiable compounds, and that verification happens before the first injection, not after the failed experiment.

References

Peer-reviewed sources on NAD+ indexed in PubMed, listed for research context. Real Peptides supplies NAD+ for laboratory research use only.

NAD⁺ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence. Ageing research reviews, 2026. PMID 41655607. doi:10.1016/j.arr.2026.103057
NAD(+) restores proteostasis through splicing-dependent autophagy. Autophagy, 2026. PMID 41313318. doi:10.1080/15548627.2025.2596679
Endothelial NAD(+) depletion drives vascular senescence and neuroinflammation via mtDNA-cGAS/STING-CD38 signaling in Alzheimer's disease. Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026. PMID 42033099. doi:10.1002/alz.71423
NAD+ and Sirt5 restore mitochondrial bioenergetics failure and improve locomotor defects caused by sucla2 mutations. JCI insight, 2026. PMID 41574612. doi:10.1172/jci.insight.181812
NAD(+) depletion drives age-related monocyte hyperinflammation after stroke and is reversed by nicotinamide riboside. Journal of neuroinflammation, 2025. PMID 41299539. doi:10.1186/s12974-025-03638-6
Lactate dehydrogenase A-coupled NAD(+) regeneration is critical for acute myeloid leukemia cell survival. Cancer & metabolism, 2025. PMID 40390151. doi:10.1186/s40170-025-00392-4
FOXO1-NMNAT3 axis dysregulation promotes doxorubicin cardiotoxicity: NAD(+) replenishment as a redox-targeted antioxidant therapy. Redox report : communications in free radical research, 2025. PMID 41021886. doi:10.1080/13510002.2025.2565033
NAD+ prevents chronic kidney disease by activating renal tubular metabolism. JCI insight, 2025. PMID 40059824. doi:10.1172/jci.insight.181443

Questions

It means 98 grams of every 100 grams in the sample is the target NAD+ molecule, as measured by high-performance liquid chromatography. The remaining 2% includes water, residual salts, and trace impurities like degradation products or leftover solvents from synthesis. HPLC separates compounds physically before measuring them, so this percentage reflects actual molecular composition — not just UV absorbance or appearance. Purity below 98% introduces too much variability for dose-dependent research, and the missing percentages represent unidentified substances that may interfere with your assay.

No. ‘Conforms’ means the supplier tested for metals and decided the result met their internal threshold, but without numeric values, you can’t verify that claim or compare batches. ICH Q3D guidelines and USP Chapter <232> require quantified measurements for lead, arsenic, cadmium, and mercury because these metals accumulate over time and interfere with enzymatic assays even at low concentrations. A proper COA lists each metal in ppm with the detection limit specified — anything less isn’t traceable quality documentation.

Check that the batch number printed on your vial label exactly matches the batch number listed on the COA, and confirm the test date is within 12 months of your order. If the numbers don’t match or the COA is undated, request batch-specific documentation from the supplier before using the peptide. Batch traceability is the only way to confirm the tested sample corresponds to what you’re injecting — without it, the COA could be from a different synthesis run, a ‘golden batch’ tested once and reused, or completely fabricated.

Endotoxin levels should be below 50 EU/mg (endotoxin units per milligram) for research-grade peptides used in cell culture or immunological assays. Bacterial endotoxin, a byproduct of fermentation-based synthesis, triggers inflammatory cytokine release at concentrations as low as 10–20 EU/mg, which confounds immune response studies and affects cell viability in culture. If the COA doesn’t list endotoxin levels or shows values above 50 EU/mg, the peptide is unsuitable for biological research without additional purification using polymyxin B affinity chromatography or equivalent endotoxin removal.

Because purity percentage is meaningless without knowing how it was measured. Spectrophotometry can report ‘99% purity’ by measuring UV absorbance at 260 nm, but it can’t differentiate NAD+ from oxidised NADH, nicotinamide mononucleotide, or other structurally similar molecules with overlapping spectra. HPLC physically separates these compounds before quantifying them, so a 98% purity claim by HPLC is far more reliable than a 99% claim by UV absorbance. Without a validated chromatographic method, the purity number is a marketing claim, not a measurement.

Use it only for preliminary screening or non-dose-sensitive applications, and request a higher-purity batch for critical experiments. The 2% gap between 96% and 98% purity doubles the impurity load from 2% to 4%, and that unknown 4% could be degraded NAD+, residual solvents, or bacterial contaminants — none of which are inert. For dose-response assays, receptor binding studies, or metabolic tracing where precise molarity matters, the uncontrolled variability introduced by 4% impurities shifts your confidence intervals and makes results non-reproducible across batches.

COAs are typically considered valid for 12 months from the test date, assuming proper storage conditions were maintained. NAD+ degrades over time through oxidation and hydrolysis, especially if exposed to heat, light, or moisture, so a COA from 18–24 months ago no longer reflects the current peptide quality in your vial. If you’re using older stock, request retesting or verify purity independently via HPLC before starting experiments — peptide degradation is gradual but cumulative, and results obtained with degraded compound are not reproducible.

A batch-specific COA reports analytical results from the exact synthesis batch you received, identified by a unique batch number printed on both the COA and your vial. A generic COA is a template report listing typical values or results from a ‘golden batch’ tested once and reused across multiple shipments without retesting. Generic COAs provide no traceability — you can’t verify the peptide in your vial matches the tested sample, and you have no way to identify quality drift across production runs. Only batch-specific COAs with matching numbers are valid quality assurance documents.

Yes, and you should. A legitimate supplier provides the full HPLC chromatogram, integration report, and mass spectrum upon request because these are the actual analytical data behind the summary COA. The chromatogram shows peak separation and retention time, the integration report quantifies each peak’s area percentage, and the MS spectrum confirms molecular weight matches NAD+ at 663.43 Da. If the supplier hesitates, delays, or refuses to provide raw data, it’s a strong signal they didn’t perform the testing themselves or the results don’t support the claimed purity.

A complete COA quantifies at least three residual solvents: acetonitrile (limit <410 ppm), methanol (limit <3000 ppm), and dimethylformamide or DMF (limit <880 ppm), per ICH Q3C Class 2 solvent guidelines. These solvents are used during peptide purification and can remain in trace amounts if drying isn't exhaustive. High residual solvent levels indicate incomplete purification, and over time, these solvents degrade peptide stability and introduce cytotoxicity in cell-based assays. A COA listing 'solvents: within limits' without numeric values isn't verifiable.

No. Mass spectrometry confirms molecular weight and verifies you have the correct compound, but it doesn’t measure purity percentage or quantify impurities. MS tells you the molecular formula is correct at 663.43 Da for NAD+, but a sample could be 85% NAD+ and 15% degradation products with similar mass, and MS alone wouldn’t flag that. HPLC quantifies the mass fraction of each component, which is why the strongest COAs combine both: HPLC for purity measurement, MS for identity confirmation. MS without HPLC is molecular verification, not quality assurance.

It means the supplier measured total contamination at 2% or less but didn’t characterise what those impurities are — which provides minimal actionable information. The 2% could be water and salts (acceptable) or nicotinamide riboside and bacterial endotoxin (not acceptable). USP Chapter 1225 requires that individual unspecified impurities not exceed 0.5%, so a COA listing only total impurities doesn’t prove compliance with that standard. Without an itemised impurity profile, you can’t assess whether the contaminants present will interfere with your specific assay or degrade faster than the target compound during storage.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA